Logo image of ICAD

ICAD INC (ICAD) Stock Fundamental Analysis

NASDAQ:ICAD - Nasdaq - US44934S2068 - Common Stock - Currency: USD

3.43  +0.01 (+0.29%)

Fundamental Rating

3

Overall ICAD gets a fundamental rating of 3 out of 10. We evaluated ICAD against 37 industry peers in the Health Care Technology industry. No worries on liquidiy or solvency for ICAD as it has an excellent financial health rating, but there are worries on the profitability. ICAD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ICAD had negative earnings in the past year.
ICAD had a negative operating cash flow in the past year.
ICAD had negative earnings in each of the past 5 years.
ICAD had a negative operating cash flow in each of the past 5 years.
ICAD Yearly Net Income VS EBIT VS OCF VS FCFICAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -14.96%, ICAD perfoms like the industry average, outperforming 56.76% of the companies in the same industry.
ICAD has a Return On Equity of -19.58%. This is comparable to the rest of the industry: ICAD outperforms 56.76% of its industry peers.
Industry RankSector Rank
ROA -14.96%
ROE -19.58%
ROIC N/A
ROA(3y)-17.69%
ROA(5y)-20.57%
ROE(3y)-24.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
ICAD Yearly ROA, ROE, ROICICAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

Looking at the Gross Margin, with a value of 84.83%, ICAD belongs to the top of the industry, outperforming 86.49% of the companies in the same industry.
In the last couple of years the Gross Margin of ICAD has grown nicely.
ICAD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5Y1.87%
ICAD Yearly Profit, Operating, Gross MarginsICAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

ICAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ICAD has about the same amount of shares outstanding.
Compared to 5 years ago, ICAD has more shares outstanding
There is no outstanding debt for ICAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ICAD Yearly Shares OutstandingICAD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ICAD Yearly Total Debt VS Total AssetsICAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -3.41, we must say that ICAD is in the distress zone and has some risk of bankruptcy.
ICAD has a Altman-Z score of -3.41. This is in the lower half of the industry: ICAD underperforms 64.86% of its industry peers.
ICAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.41
ROIC/WACCN/A
WACC10.57%
ICAD Yearly LT Debt VS Equity VS FCFICAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

ICAD has a Current Ratio of 3.50. This indicates that ICAD is financially healthy and has no problem in meeting its short term obligations.
ICAD's Current ratio of 3.50 is amongst the best of the industry. ICAD outperforms 81.08% of its industry peers.
A Quick Ratio of 3.40 indicates that ICAD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.40, ICAD belongs to the top of the industry, outperforming 81.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 3.4
ICAD Yearly Current Assets VS Current LiabilitesICAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

ICAD shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.55%.
Looking at the last year, ICAD shows a quite strong growth in Revenue. The Revenue has grown by 13.21% in the last year.
The Revenue has been decreasing by -8.95% on average over the past years.
EPS 1Y (TTM)4.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-160%
Revenue 1Y (TTM)13.21%
Revenue growth 3Y-16.47%
Revenue growth 5Y-8.95%
Sales Q2Q%14.07%

3.2 Future

Based on estimates for the next years, ICAD will show a very strong growth in Earnings Per Share. The EPS will grow by 25.48% on average per year.
ICAD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.95% yearly.
EPS Next Y-6.86%
EPS Next 2Y19.04%
EPS Next 3Y25.48%
EPS Next 5YN/A
Revenue Next Year3.63%
Revenue Next 2Y9.06%
Revenue Next 3Y6.95%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ICAD Yearly Revenue VS EstimatesICAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
ICAD Yearly EPS VS EstimatesICAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ICAD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICAD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICAD Price Earnings VS Forward Price EarningsICAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICAD Per share dataICAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ICAD's earnings are expected to grow with 25.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.04%
EPS Next 3Y25.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ICAD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICAD INC

NASDAQ:ICAD (4/30/2025, 3:58:53 PM)

3.43

+0.01 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-19 2025-03-19/amc
Earnings (Next)05-19 2025-05-19/bmo
Inst Owners23.48%
Inst Owner Change-6.2%
Ins Owners5.63%
Ins Owner Change0.69%
Market Cap93.88M
Analysts84
Price Target3.57 (4.08%)
Short Float %1.04%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.81%
Min EPS beat(2)17.64%
Max EPS beat(2)43.98%
EPS beat(4)4
Avg EPS beat(4)24%
Min EPS beat(4)11.77%
Max EPS beat(4)43.98%
EPS beat(8)7
Avg EPS beat(8)42.78%
EPS beat(12)8
Avg EPS beat(12)27.33%
EPS beat(16)9
Avg EPS beat(16)16.68%
Revenue beat(2)1
Avg Revenue beat(2)0.64%
Min Revenue beat(2)-8.54%
Max Revenue beat(2)9.83%
Revenue beat(4)3
Avg Revenue beat(4)5.51%
Min Revenue beat(4)-8.54%
Max Revenue beat(4)11.48%
Revenue beat(8)4
Avg Revenue beat(8)-2.04%
Revenue beat(12)4
Avg Revenue beat(12)-11.07%
Revenue beat(16)5
Avg Revenue beat(16)-9.5%
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.17%
EPS NY rev (1m)0%
EPS NY rev (3m)10.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.39%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)1.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.79
P/FCF N/A
P/OCF N/A
P/B 3.27
P/tB 4.64
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.72
BVpS1.05
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.96%
ROE -19.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.83%
FCFM N/A
ROA(3y)-17.69%
ROA(5y)-20.57%
ROE(3y)-24.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5Y1.87%
F-Score3
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.92%
Cap/Sales 0.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.5
Quick Ratio 3.4
Altman-Z -3.41
F-Score3
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)118.09%
Cap/Depr(5y)108.13%
Cap/Sales(3y)2.69%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-160%
EPS Next Y-6.86%
EPS Next 2Y19.04%
EPS Next 3Y25.48%
EPS Next 5YN/A
Revenue 1Y (TTM)13.21%
Revenue growth 3Y-16.47%
Revenue growth 5Y-8.95%
Sales Q2Q%14.07%
Revenue Next Year3.63%
Revenue Next 2Y9.06%
Revenue Next 3Y6.95%
Revenue Next 5YN/A
EBIT growth 1Y20.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.19%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.53%
OCF growth 3YN/A
OCF growth 5YN/A